Engineering bionic nano system and preparation method and application thereof

By designing engineered bionic nanosystems MP@AL NPs, combining tumor cell membranes and pH-responsive liposome loads L-Arg and Lox, releasing NO and promoting lactic acid depletion, solving the problem that traditional gas therapy cannot reverse the tumor immunosuppressive microenvironment. 'Gas-immuno-metabolic therapy' was achieved, which significantly enhanced the anti-tumor efficacy.

CN119033725APending Publication Date: 2024-11-29ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411205080.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Traditional gas therapy has shortcomings in reversing the tumor immunosuppressive microenvironment, and the rapid spread of gas molecules leads to low efficacy, making it difficult to achieve the bidirectional regulation of ‘gas-immunometabolic therapy’.

Method used

An engineered bionic nanosystem MP@AL NPs was designed to release NO in a high H2O2 environment by combining tumor cell membranes and pH-responsive liposome loading L-Arg and lactate oxidase (Lox), promoting lactic acid depletion and reversing immunity Inhibit the microenvironment and activate the immune response.

Benefits of technology

The ‘gas-immuno-metabolic therapy’ was achieved, which enhanced the efficacy of anti-tumor immunotherapy, ensured the synergy with PD-L1 antibodies, and significantly inhibited tumor growth and recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033725A_ABST
    Figure CN119033725A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly discloses an engineering bionic nano system as well as a preparation method and application thereof. The engineering bionic nano-system (MP (at) AL NPs) is nano-particles, the structure of the engineering bionic nano-system is that a fusion membrane of a tumor cell membrane (M) and a pH response type liposome (P) is loaded with L-arginine (L-Arg) and lactate oxidase (Lox), the Lox is used for depleting high-level metabolic waste lactic acid in a tumor microenvironment, and the L-Arg can release tumor therapeutic gas nitric oxide (NO) under the stimulation of high-concentration H2O2 in the tumor microenvironment. NO generated by the engineering bionic nano system not only triggers death of tumor immunogen cells, but also effectively promotes lactic acid depletion reaction, the limitation that a traditional tumor gas therapy method cannot effectively reverse tumor immunosuppression microenvironment is broken, anti-tumor immune response and long-term immune memory are activated, the synergistic effect with a PD-L1 antibody is ensured, and the tumor immunosuppressive effect is improved. The medicine has a good effect of inhibiting tumor growth and recurrence.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to an engineering bionic nanosystem and a preparation method and application thereof. Background Art

[0002] Gas therapy has made great progress in cancer treatment due to its high efficiency and good biosafety. As a green cancer treatment, it focuses on introducing therapeutic gases such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S) into tumors, leading to tumor immunogenic cell death (ICD) and inducing anti-tumor immune responses. Various types of gas therapy strategies have been widely used in preclinical studies and even clinical trials to prevent tumor growth and metastasis. However, low patient response rates continue to hinder the clinical use of gas therapy, mainly due to the persistent tumor immunosuppressive microenvironment that will inevitably undermine the anti-tumor efficiency of gas therapy, as well as the rapid and free diffusion characteristics of the gas molecules themselves.

[0003] Given the close crosstalk between cancer metabolism and the tumor immunosuppressive microenvironment, taming metabolites in cancer cells provides an effective solution, such as reshaping the immunosuppressive microenvironment by consuming tumor metabolic waste. Among the complex metabolic pathways of tumors, overactivation of glycolysis is a universal hallmark of cancer. Tumor cells use a large amount of glucose and convert it into the metabolite lactate through glycolysis. Lactate accumulation not only leads to an acidic tumor microenvironment, but also causes a tumor immunosuppressive microenvironment by inducing M2 polarization of tumor-associated macrophages, promoting the generation of myeloid-derived suppressor cells, and inhibiting T cell activation. Increasing evidence shows that downregulation of tumor cell lactate secretion, disruption of lactate transporters, and direct depletion of lactate disrupt lactate metabolism, which is expected to reverse the tumor immunosuppressive microenvironment and enhance anti-tumor effects. Therefore, targeting lactate to reshape the tumor immunosuppressive microenvironment may be an attractive oncology strategy to synergize gas therapy, enhance its therapeutic effect, and achieve "gas-immunometabolism therapy."

[0004] In recent years, advances in nanotechnology have led to the rapid development of therapeutic nanomaterials for precisely targeting tumor microenvironment responses. However, achieving bidirectional regulation such as “gas-immunometabolism therapy” remains a daunting task for currently available gas-generating nanosystems. Lactate oxidase (Lox) has been industrialized and commercialized due to its excellent lactate depletion properties. It has been reported that Lox, together with oxygen, promotes lactate catabolism, thereby inhibiting the formation of a tumor immunosuppressive microenvironment. However, the activity of Lox may be affected by the hypoxic tumor microenvironment and the byproduct of the oxidation reaction, hydrogen peroxide (H2O2). NO is used as a classic tumor therapeutic gas, and its endogenous donor L-arginine (L-Arg) can be oxidized by reactive oxygen species (ROS, such as H2O2 and O2) to produce NO. Interestingly, NO can also improve the hypoxic tumor microenvironment by inhibiting tumor cell respiration and oxygen consumption, which in turn promotes the efficiency of Lox in depleting the immune-related metabolite lactate. In view of this, we designed a novel engineered biomimetic NO-generating nanosystem, whose released NO not only triggers tumor immunogenic cell death but also effectively promotes lactate depletion response and reshapes the tumor immunosuppressive microenvironment, thereby realizing “gas-immunometabolism therapy” for the first time and ultimately expanding the efficacy of tumor immunotherapy. Summary of the invention

[0005] The purpose of the present invention is to provide an engineered bionic nanosystem that can trigger "gas-immunometabolism therapy", which overcomes the defect that traditional gas therapy cannot reverse the tumor immunosuppressive microenvironment, thereby enhancing anti-tumor immunotherapy.

[0006] In order to achieve the above object, the specific technical solution adopted by the present invention is as follows:

[0007] In the first aspect, the present invention provides an engineered bionic nanosystem MP@AL NPs, which is a nanoparticle structured as a fusion membrane of a tumor cell membrane (tumour cell membrane, M) and a pH-responsive liposome (pH-responsive liposomes, P) loaded with L-Arg and Lox. The Lox is used to deplete the high level of metabolic waste lactic acid in the tumor microenvironment, and L-Arg can release tumor therapeutic gas NO under the stimulation of high concentration of H2O2 in the tumor microenvironment.

[0008] The NO continuously produced by the engineered bionic nanosystem (MP@AL NPs) of the present invention, on the one hand, causes mitochondrial dysfunction in tumor cells, reduces oxygen consumption, and promotes the efficiency of Lox in lactate decomposition, thereby reversing the tumor immunosuppressive microenvironment induced by lactate; on the other hand, NO effectively triggers immunogenic cell death, activates anti-tumor immune response and long-term immune memory, and ensures synergy with PD-L1 antibodies, which has a good effect on inhibiting tumor growth and recurrence. Compared with the unresolved or controversial biosafety issues of nanocarriers for gas therapy or immune drugs developed in the past, the components used to construct the engineered bionic nanosystem here are endogenous to the human body, and therefore, are safer and more reliable, with broad prospects for clinical transformation.

[0009] In a second aspect, the present invention provides a method for preparing the above-mentioned engineering bionic nanosystem, which specifically comprises the following steps:

[0010] S1. Synthesis of pH-responsive liposome-loaded L-Arg and Lox nanoparticles (P@AL NPs): Soybean lecithin, cholesterol and DSPE-Hyd-PEG-COOH(P) were dissolved in chloroform and rotary evaporated to obtain a phospholipid membrane; PBS, Lox and L-Arg were added dropwise to the phospholipid membrane, and the membrane was dissolved by ultrasound, and then the porous membrane was extruded to obtain P@AL NPs;

[0011] S2. Tumor cell membranes are coated on the surface of P@AL NPs to form an engineered bionic nanosystem (MP@AL NPs): cancer cell lines are disrupted using a homogenizer, sucrose solution is mixed with the cell homogenate, and the mixture is centrifuged to obtain tumor cell membranes (M); M is extruded using a porous membrane, and then P@AL is added, and then co-extruded using a porous membrane, and then centrifuged after extrusion to remove excess M and obtain M-coated P@AL NPs (MP@AL NPs).

[0012] Preferably, in step S1, the rotary evaporation is performed at 45-55°C for 20-40 minutes, more preferably at 50°C for 30 minutes.

[0013] Preferably, in step S1, when the porous membrane is extruded, a 200nm porous membrane is first used to extrude back and forth, and then a 100nm porous membrane is used to extrude back and forth, and the final P@AL NPs particle size is slightly larger than 100nm. The 200nm porous membrane is used for extrusion in turn for transition, and then the 100nm porous membrane is used for extrusion for better effect.

[0014] Preferably, in step S2, the mass ratio of the extruded tumor cell membrane (M) to the P@AL NPs is 1:2.5-3.5, more preferably 1:3.

[0015] Preferably, in step S2, the centrifugation of the mixture includes two steps of centrifugation, firstly centrifugation at 2000g for 8-15 minutes, and then centrifugation of the obtained supernatant at 3000g for 25-35 minutes, and the precipitate is the tumor cell membrane.

[0016] Preferably, in step S2, M is extruded with a 200nm porous membrane, and then P@AL NPs are added, and then co-extruded with a 100nm porous membrane. The diameter of the extruded MP@AL NPs is 100-130nm. If the particle size is too large, it cannot reach the tumor and will be phagocytosed by macrophages.

[0017] In the third aspect, the present invention provides the application of the above-mentioned engineering bionic nanosystem in the preparation of anti-tumor drugs. The present invention has repeatedly verified through in vitro experiments, 3D tumor sphere models, in vivo in situ mouse HCC-SM models, and simulated tumor long-term immune memory models that the engineering bionic nanosystem can achieve a powerful anti-tumor effect, inhibit distant tumors and metastasis, and improve long-term survival rate.

[0018] Furthermore, the tumor includes advanced liver cancer spinal metastases. The present invention uses clinically challenging advanced hepatocellular carcinoma spinal metastases (HCC-SM) as a tumor treatment model, and found that lactate metabolism was significantly upregulated in clinically advanced HCC-SM patients and HCC-SM mice, further indicating that the tumor immunosuppressive microenvironment caused by lactate may be related to tumor growth and metastasis, leading to immune escape, showing the preliminary feasibility of "gas-immunometabolism therapy". On this basis, the present invention verifies the good effect of the engineered bionic nanosystem MP@AL NPs and PD-L1 antibodies in synergistically inhibiting HCC-SM tumor growth and recurrence, showing the success of the "gas-immunometabolism therapy" mediated by the engineered bionic nanosystem.

[0019] The present invention has the following beneficial effects:

[0020] (1) The engineered bionic nanosystem of the present invention can trigger "gas-immunometabolism therapy" and can be applied to the treatment of spinal metastases of advanced liver cancer, which is extremely challenging in clinical treatment. The NO produced by the engineered bionic nanosystem (MP@AL NPs) not only triggers tumor immunogenic cell death, but also effectively promotes lactate depletion reaction, breaking the limitation that traditional tumor gas therapy cannot effectively reverse the tumor immunosuppressive microenvironment, activating anti-tumor immune response and long-term immune memory, and ensuring synergy with PD-L1 antibody, which has a good effect on inhibiting tumor growth and recurrence.

[0021] (2) The surface of the engineered bionic nanosystem (MP@AL NPs) prepared by the present invention is composed of a tumor cell membrane and a pH-responsive liposome fusion membrane. The different functional proteins on the tumor cell membrane give MP@AL NPs excellent homologous tumor targeting, and the pH-responsive liposome enables the MP@AL NPs to be controllably released in the acidic tumor microenvironment.

[0022] (3) The preparation method of the present invention is simple and efficient, has good material dispersibility, high drug loading capacity, good biocompatibility, no waste and no pollution in the whole process, high repeatability, and is suitable for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 : Results of the research experiment on the relationship between lactic acid and HCC-SM progression in Example 1 of the present invention. In the figure, a represents the expression levels of Ki67, LDHA and MCT4 in tissue samples resected from HCC and HCC-SM patients; b represents the expression levels of Ki67, LDHA and MCT4 in tissue samples resected from HCC and HCC-SM mice; ce: the expression levels of Ki67, LDHA and MCT4 in liver cancer and bone metastasis samples in the Cancer Genome Atlas (TCGA) database.

[0024] Figure 2 : The result diagram of the preparation and identification of the engineering bionic nanosystem in Example 2 of the present invention. In the figure, a represents a schematic diagram of the manufacturing process of P@AL NPs and MP@AL NPs; b represents TEM characterization; c represents the analysis of nanoparticle Coomassie brilliant blue staining; d represents the particle size distribution curve; e represents the zeta potential; f represents the polydispersity index (PDI); g represents the protein standard absorption curve; i represents the L-Arg standard absorption curve; j represents the cumulative release efficiency of L-Arg at different pH.

[0025] Figure 3 : The result diagram of the in vitro functional evaluation of the engineering biomimetic nanosystem in Example 2 of the present invention. In the figure, a represents the quantitative diagram of the ability of MP@AL NPs to consume lactic acid; b represents the quantitative diagram of the ability of MP@AL NPs to generate H2O2 by consuming lactic acid; c represents the lactic acid concentration in the culture medium supernatant after different treatments of tumor cells; d represents the quantitative diagram of the ability of MP@AL NPs to generate NO under different pH conditions; e represents the quantitative diagram of the ability of MP@AL NPs to generate NO under different lactic acid concentrations; f represents a schematic diagram of the intracellular triggering of "gas-immunometabolism therapy" by MP@ALNPs; g represents the intracellular NO fluorescence diagram; h represents the quantitative diagram of cellular oxygen consumption rate (OCR).

[0026] Figure 4: The result diagram of the in vitro anti-tumor efficacy of the engineered bionic nanosystem in Example 3 of the present invention. In the figure, a represents the cytotoxicity of MP@AL NPs at different concentrations after treating tumor cells for 24 hours; b represents the cytotoxicity of MP@AL NPs at different concentrations after treating tumor cells for 48 hours; c represents the quantitative situation of the cytotoxicity of MP@AL NPs to tumor cells with or without lactic acid in the culture medium; d represents the AM / PI fluorescence image after MP@AL NPs treat tumor cells; e represents the fluorescence image of tumor cells taking up MP@AL NPs, in which CY5.5 dye labels MP@AL NPs, and Phalloidine is a F-Actin microfilament protein fluorescent dye that can display the entire cell morphology and outline; f represents the fluorescence image of tumor spheres taking up MP@AL NPs; g represents the quantitative image of f.

[0027] Figure 5 : The result diagram of the in vitro anti-tumor efficacy of the engineered bionic nanosystem in Example 3 of the present invention. In the figure, a represents the schematic diagram of ICD induced by MP@AL NPs in vitro; b represents the result of enzyme-linked immunosorbent assay (ELISA) analysis of extracellular ATP level; c represents the result of enzyme-linked immunosorbent assay (ELISA) analysis of extracellular high mobility group protein B1 (HMGB1) level; d represents the fluorescence image of calreticulin (CRT) and HMGB1 after MP@AL NPs treated tumor cells; e and f represent the levels of IL-6 and TNF-α in mouse blood, respectively; g represents the flow cytometry analysis results of mature dendritic cells (DCs).

[0028] Figure 6 : The result diagram of the in vivo anti-tumor efficacy of the engineered bionic nanosystem in Example 4 of the present invention. In the figure, a represents a schematic diagram of the MP@AL NPs treatment process; b represents an in vivo tumor bioluminescence image of HCC-SM; c represents a schematic diagram of evaluating the ability of MP@AL NPs to consume lactic acid in HCC-SM tumors in vivo; d represents a quantitative diagram of MP@AL NPs consuming lactic acid in HCC-SM tumors in vivo; e is the quantitative analysis result of b; f represents an in vitro tumor image; g represents a quantitative diagram of f; h represents the weight of mice after MP@AL NPs treated HCC-SM; i represents an in vitro gross image of HCC-SM; j represents the quantitative analysis result of tumor volume; k represents a micro-CT image of mouse vertebrae; l represents the paralysis rate of HCC-SM mice.

[0029] Figure 7: The result diagram of the in vivo anti-tumor efficacy of the engineered bionic nanosystem in Example 4 of the present invention. In the figure, a represents the tissue immunofluorescence staining images of IL-6, CRT and HMGB1 in HCC-SM mice; b represents the flow cytometry analysis results of mature DCs, CD8+T cells and Tregs T cells from top to bottom; c represents the multi-color tissue immunofluorescence staining images of Ki67-positive tumor cells and CD4+, CD8+ and Foxp3+T cells in HCC-SM tissue samples; d represents the expression level of IL-6 in the blood; e represents the expression level of IFN-γ in the blood; f represents the expression level of TNF-α in the blood.

[0030] Figure 8 : The result diagram of the long-term immune memory effect induced by the engineered bionic nanosystem in Example 5 of the present invention. a represents the schematic diagram of the establishment and treatment of the HCC long-term immune memory model; b represents the general picture of the recurrent tumor after 60 days; c represents the time of tumor recurrence; d represents the tissue immunofluorescence staining image of CD4+ or CD8+ T cells in the HCC-SM tissue sample; e and f represent the quantitative graph of d; g represents the quantitative graph of i; h represents the quantitative graph of j; i represents the flow cytometry result graph of CD8+ effector memory T cells; j represents the flow cytometry result graph of CD4+ effector memory T cells. DETAILED DESCRIPTION

[0031] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.

[0032] Example 1: Experimental study on the relationship between lactic acid and HCC-SM progression

[0033] This example explores the relationship between lactate and the progression of malignant tumors. In view of the high incidence of liver cancer and advanced HCC-SM, it is extremely important to study how to improve the prognosis of patients with liver cancer and HCC-SM by affecting lactate levels. Here, the levels of Ki67, a proliferation marker, lactate dehydrogenase A (LDHA), a lactate production marker, and monocarboxylate transporter 4 (MCT4), a lactate efflux marker, in HCC in situ and HCC-SM in clinical patients and mice were analyzed by immunohistochemistry. The results showed that the levels of Ki67, LDHA and MCT4 in clinical patients and mice were significantly upregulated in HCC and HCC-SM compared with para-cancer (Para-HCC, Para-HCC-SM), and the lactate metabolism indicators in HCC-SM were significantly upregulated relative to in situ HCC ( Figure 1 a, b). In addition, the expression of Ki67, LDHA, and MCT4 was further evaluated by liver cancer and bone metastasis samples from the Cancer Genome Atlas (TCGA) database, including 50 patients with primary HCC and 9 patients with secondary bone metastasis of HCC. The results showed that compared with primary HCC samples, HCC bone metastasis samples showed significantly increased expression of Ki67, LDHA, and MCT4 ( Figure 1 ce).

[0034] These results reveal that elevated lactate levels lead to the formation of a tumor immunosuppressive microenvironment, which promotes tumor growth, metastasis, and recurrence. Therefore, we believe that targeting the lactate-induced tumor immunosuppressive microenvironment may be a promising therapeutic strategy in the clinical management of cancer.

[0035] Example 2: Preparation, characterization, detection and functional evaluation of engineered bionic nanosystems

[0036] This embodiment provides an engineering bionic nanosystem, which is prepared by the following method:

[0037] First, the synthesis of pH-responsive liposome-loaded L-Arg and Lox nanoparticles (P@AL NPs) was performed: 8.5 mg soybean lecithin, 1 mg cholesterol, and 2.5 mg DSPE-Hyd-PEG-COOH (P) were dissolved in 20 mL chloroform. The phospholipid membrane was obtained by evaporation at 50 ° C for 30 min using a rotary evaporator. Then, 6 mL PBS, 1 mg / mL Lox, and 3 mg / mL L-Arg were dropped into the flask to dissolve the membrane. After dissolving for 5 min using an ultrasonic cleaner, the membrane was squeezed back and forth 10 times with a 200 nm porous membrane and then squeezed back and forth 10 times with a 100 nm porous membrane to obtain P@AL NPs.

[0038] The second step is to coat the tumor cell membrane on the surface of P@AL NPs to form an engineered biomimetic nanosystem (MP@AL NPs): The Heap1-6 liver cancer cell line containing 1% protease inhibitor (EDTA-free) was disrupted within 1 hour using an IKAT18 alkaline homogenizer. Then 1M sucrose was mixed with the cell homogenate to finally reach a 0.25M sucrose concentration, and the mixture was centrifuged (2000×g) at 4°C for about 10 minutes. The resulting supernatant was centrifuged (3000×g) for 30 minutes to collect the cancer cell membrane and washed twice with buffer in the presence of 0.25M sucrose for purification. To prepare MP@AL NPs, we extruded tumor cell membranes (M) with a 200nm porous membrane and then added P@AL NPs (1:3, mass / mass). After coextrusion with a 100 nm porous membrane for 10 times, the product was centrifuged again at 4 °C (10,000 × g) for 10 min to remove excess M, and the precipitate was collected to obtain M-coated P@AL NPs (denoted as MP@AL NPs). The preparation process of MP@LNPs (without L-Arg), MP@ANPs (without Lox), and MP NPs (without Lox and L-Arg) was similar to that of MP@AL NPs.

[0039] Characterization test:

[0040] The obtained MP@AL NPs were characterized ( Figure 2 a). Transmission electron microscopy (TEM) images show that the obtained P@AL NPs and MP@AL NPs have nearly spherical nanostructures with an average diameter slightly larger than 100 nm. In addition, MP@AL NPs have an obvious core-shell structure ( Figure 2 b). Protein contents in tumor cell membrane (M), tumor cell membrane and liposome fusion membrane (MP), and MP@AL NPs were identified by Coomassie Brilliant Blue staining ( Figure 2 c). The results showed that the protein components of the tumor cell membrane were well preserved in MP and MP@AL NPs. This verified the effective fusion of M with P@AL NPs and indicated that the encapsulation process of tumor cell membrane in P@AL NPs had no effect on the tumor cell membrane protein content. In addition, dynamic light scattering (DLS) was performed to examine the particle size and zeta potential of various nanoparticles. The particle sizes of MP NPs (117.32nm), MP@A NPs (122.58nm), MP@L NPs (120.38nm), and MP@AL NPs (126.57nm) were similar and larger than those of P@AL NPs (105.23nm)( Figure 2 d). The zeta potential of MP@AL NPs (-2.63 mV) is lower than that of P@AL NPs (-1.24 mV). In short, tumor cell membranes were successfully coated on the surface of P@AL NPs ( Figure 2 e). The PDI of MP@AL NPs is lower than 0.2, indicating that MP@AL NPs have uniform particle size ( Figure 2 f). In addition, the protein content in MP@AL NPs (3.22 mg / mL) and MP@A NPs (2.96 mg / mL) was determined by BCA protein assay kit and verified by protein standard curve, which proved that Lox was successfully encapsulated into MP@AL NPs with a content of about 0.26 mg / mL. The encapsulation rate and loading rate of Lox were calculated to be 78.37% and 2.89%, respectively ( Figure 2 g), where the embedding rate is calculated based on the ratio of the target substance encapsulated in the engineering biomimetic nanosystem to the total amount of the target substance used, and the loading rate is calculated based on the ratio of the target substance loaded in the engineering biomimetic nanosystem to the total amount of the engineering biomimetic nanosystem required for synthesis. The content of L-Arg in MP@AL NPs (12.48 mM) and MP@L NPs (0 mM) was obtained by the L-Arg assay kit and verified by the L-Arg standard absorption curve ( Figure 2 i) Unexpectedly, the drug release rate increased after adding MP@AL NPs to low pH solution. Figure 2As shown in j, the L-Arg release rate increased after MP@AL NPs were used as a therapeutic system under tumor pathological conditions (pH = 5.0), but decreased under physiological conditions (pH = 7.4) ( Figure 2 j), indicating that MP@AL NPs can target the acidic microenvironment of tumors (pH = 5.0) and controllably release drugs.

[0041] Functional assessment:

[0042] To evaluate the lactate depletion capacity of MP@AL NPs, we immersed a dialysis bag containing 2 mL of MP@AL NPs (500 μg / mL) solution into a beaker containing lactic acid solution. The lactate concentration in the beaker at different time points was analyzed. Figure 3 As can be seen in a, the lactic acid concentration gradually decreased over time, indicating that the Lox loaded in MP@AL NPs still maintained catalytic performance throughout the reaction process ( Figure 3 a). Subsequently, the ability of MP@AL NPs to catalyze the production of H2O2 from lactic acid was measured at different lactic acid concentrations. Figure 3 b The results show that the ability to produce H2O2 depends on the lactic acid concentration ( Figure 3 b). To evaluate the lactate depletion capacity of MP@AL NPs at the cellular level, we obtained the supernatant of the cell culture medium and measured the relevant indicators after treating liver cancer cells with PBS, Lox, and MP@ALNPs for 24 hours (equal concentration of Lox, 4 μg / mL). The results showed that the lactate concentration decreased significantly by about 85% after Lox and MP@AL NPs treated tumor cells compared with the PBS group, thus verifying the ability of MP@AL NPs (200 μg / mL) to consume lactate ( Figure 3 c).

[0043] Studies have reported that L-Arg, as an endogenous donor of NO, can be oxidized by H2O2, a byproduct of lactate consumption, to produce NO. Figure 3 d, it was found that compared with a neutral environment (pH = 7.4), an acidic environment (pH = 5.0) was more likely to promote L-Arg to produce NO, which indicated that an acidic environment significantly increased the reaction rate of L-Arg and H2O2 ( Figure 3 d). After adding MP@AL NPs to a solution containing lactic acid, Lox first converts lactic acid into H2O2, which is then responsible for oxidizing L-Arg into NO under acidic conditions, and the production of NO is proportional to the lactic acid concentration ( Figure 3 e). NO fluorescent probe further clarified that MP@AL NPs promoted the production of NO in liver cancer cells ( Figure 3g). Studies have reported that high concentrations of NO (>1 μM) induce tumor cell death, and high concentrations of NO (>0.5 μM) also irreversibly inhibit mitochondrial respiration. Therefore, the oxygen consumption rate of liver cancer cells treated with MP@AL NPs was evaluated. The results showed that MP@AL NPs led to a decrease in the oxygen consumption rate of liver cancer cells ( Figure 3 h). In summary, the function of MP@ALNPs was evaluated through a series of in vitro experiments, that is, NO produced by L-Arg mediated by MP@AL NPs inhibited tumor cell mitochondrial respiration, thereby saving the oxygen required for Lox to consume lactate ( Figure 3 f).

[0044] Example 3: In vitro anti-tumor efficacy verification experiment of engineered bionic nanosystem

[0045] The in vitro cytotoxicity of various nanoparticles was first investigated, and the results showed that MP@AL NPs exhibited weak tumor inhibition at both 24 h and 48 h, with cell viability >60% in both cases ( Figure 4 a, b). However, according to Figure 4 c Results: After adding lactic acid, MP@AL NPs treatment of liver cancer cells resulted in a significant decrease in cell viability ( Figure 4 c). We also performed live / dead cell staining to evaluate cell death after treatment of liver cancer cells with PBS, MP NPs, MP@ANPs, MP@L NPs, MP@AL NPs, and MP@AL NPs+lactic acid (equivalent concentration of L-Arg, 12.48 mM, equivalent concentration of Lox, 4 μg / mL, lactic acid, 20 μM). The results showed that cell proliferation was significantly reduced after treatment of tumor cells with MP@AL NPs+lactic acid, confirming the therapeutic potential of the engineered biomimetic nanosystem in the tumor microenvironment with high lactate levels ( Figure 4 d). Ideal endocytosis may promote the therapeutic effect of nanoparticles. To evaluate the cellular uptake ability of nanoparticles, P@AL NPs and MP@AL NPs were incubated with two-dimensional (2D) liver cancer cells and three-dimensional (3D) tumor spheres, respectively. Figure 4 The results in Figure 4 showed that the uptake of MP@AL NPs by liver cancer cells was much stronger than that of P@AL NPs, and MP@AL NPs even penetrated and deposited in the center of the tumor spheroids ( Figure 4 eg).

[0046] MP@AL NPs kill tumor cells by consuming NO generated by high-concentration lactate and strongly induce tumor ICD phenomenon ( Figure 5a). Immunofluorescence of liver cancer cells and ELISA of cell supernatants showed that MP@AL NPs significantly increased the expression of CRT and enhanced the release of extracellular ATP and HMGB1, thus verifying that MP@AL NPs effectively induced ICD in tumor cells in a high-concentration lactic acid tumor microenvironment ( Figure 5 bd). We also further studied the tumor immune activation ability of MP@AL NPs by constructing a co-incubation system and incubating tumor cells in the top chamber and immature dendritic cells (DCs) in the lower chamber, followed by different treatments. Figure 5 gFlow cytometry results showed that MP@AL NPs+lactic acid significantly promoted DCs maturation, with the highest percentage of CD80+CD86+DCs cells at 40.80%. In addition, ELISA test results showed that after treatment with MP@AL NPs+lactic acid, the expression of cytokines TNF-α and IL-6 related to DCs maturation activation was the highest ( Figure 5 e,f). In conclusion, these results indicate that MP@AL NPs-mediated “gas-immunometabolism therapy” can effectively inhibit tumor cell activity, promote DCs maturation and successfully activate immune response, ensuring excellent in vitro antitumor efficacy.

[0047] Example 4: In vivo anti-tumor efficacy verification experiment of engineered bionic nanosystem

[0048] The HCC-SM mouse model was established using C57BL / 6 mice to evaluate the in vivo antitumor efficacy of MP@AL NPs. Briefly, 1×10 6 PBS suspension of liver cancer cells. Figure 6 a shows the in vivo treatment scheme. Specifically, each group of nanoparticles was injected through the tail vein starting 7 days after tumor transplantation (day 0), twice a week, 200 μL each time, and divided into the following groups: control group (PBS), MP, MP@A, MP@L, MP@AL and MP@AL NPs+aPD-L1 groups (equal concentrations of 5.0 mg / kg L-Arg, 1.5 mg / kg Lox and 5.0 μg / g aPD-L1), and the injections were continued for 3 weeks. We performed bioluminescence imaging once a week. After the mice were sacrificed, HCC-SM tissues ( Figure 6 a) The biodistribution and targeting ability of MP@AL NPs were then analyzed. Figure 6As shown in (b), compared with P@AL NPs that cannot target tumors, the fluorescence signal of MP@AL NPs accumulated at the location of mouse HCC-SM, and the signal intensity representing MP@AL NPs was significantly enhanced at specific time intervals. The main organs were collected 24 hours after tail vein injection, and the in vitro images of HCC-SM also led to similar results, indicating that MP@AL NPs accumulated more in HCC-SM tissues compared with P@AL NPs ( Figure 6 b,e). In addition, the ability of MP@AL NPs to deplete tumor lactate in vivo was evaluated ( Figure 6 c). PBS, Lox and MP@AL NPs (200ul, equal concentration 5.0mg / kg L-Arg, 1.5mg / kg Lox) were injected respectively. 24 hours after tail vein injection, the tumor tissues were harvested and homogenized to evaluate the lactate level. Figure 6 As shown in Figure d, free Lox did not reduce tumor lactate concentration because it lacks tumor targeting ability. However, MP@AL NPs have strong tumor targeting ability, so the lactate concentration in HCC-SM tissue samples injected with MP@AL NPs was significantly decreased compared with that in the PBS / Lox group ( Figure 6 d).

[0049] Since PD-L1 antibody is proposed as one of the first-line treatment options for patients with HCC and bone metastasis, the anticancer efficacy of MP@AL NPs combined with PD-L1 antibody in vivo was further analyzed. The mice were then randomly divided into 6 groups, namely control group, MP, MP@A, MP@L, and MP@AL+aPD-L1 (MP@AL+P) groups. No obvious weight loss of mice was detected during the entire treatment process, indicating that our treatment regimen was well tolerated ( Figure 6 h). The growth of HCC-SM was then observed to evaluate the anticancer efficacy between different nanoparticle treatments. As revealed by the images acquired by the in vivo imaging system and their relative luminescence intensities, HCC-SM in the MP@A group or MP@L group showed moderate tumor growth. In contrast, the luminescence intensity of HCC-SM tumors in the MP@AL group decreased, indicating that tumor growth was inhibited. Importantly, the MP@AL+aPD-L1 combination group had the lowest fluorescence intensity among the different groups, indicating that MP@AL NPs and aPD-L1 exerted a strong synergistic anticancer effect ( Figure 6 f,g). The tumor volume measurement at the end of treatment and the gross photographs of mouse HCC-SM tumor samples were also very consistent with the results of the internal imaging system analysis ( Figure 6 i,j). Paralysis is a serious complication of SM and may shorten survival, as Figure 6As shown in Figure 1, the paralysis rates of mice in the control group, MP, MP@A, and MP@L groups were all high, but the paralysis rate in the MP@AL group was lower, and the paralysis rate in the MP@AL+aPD-L1 group was the lowest ( Figure 6 l). Bone destruction in HCC-SM specimens in vivo was evaluated by micro-CT, and the results showed that most of the lumbar vertebrae of mice in the control, MP, MP@A, and MP@L groups were severely eroded and destroyed. However, only one vertebra was involved in the spine of mice in the MP@AL group, and the erosion of the vertebra was slightly alleviated. The integrity of the spine of mice in the MP@AL+aPD-L1 group was almost completely preserved, indicating that MP@AL NPs combined with immunotherapy have an excellent effect in inhibiting bone destruction ( Figure 6 k).

[0050] Further study of MP@AL NPs triggering anti-cancer immune response in vivo. Figure 7 As shown in a, tissue immunofluorescence of HCC-SM tissue samples revealed that MP@AL NPs effectively promoted the expression of CRT, HMGB1, and IL-6 in tumor tissues. Compared with the MP@AL group, the MP@AL combined with aPD-L1 antibody group showed significantly enhanced fluorescence signals, indicating that the combined treatment of MP@AL NPs + aPD-L1 significantly enhanced the maturation of DCs ( Figure 7 a). Flow cytometry was also performed to study DCs maturation and subsequent T cell activation. The results showed that the proportion of mature DCs and CD8+T cells in HCC-SM tissue samples in the MP@AL and MP@AL+P groups was significantly upregulated, and Foxp3+Tregs T cells were significantly reduced. The immune response activation was more significant after the combination with aPD-L1 antibody, indicating that the "gas-immunometabolism therapy" mediated by engineered biomimetic nanoparticles combined with aPD-L1 can synergistically activate anti-tumor T cell immune responses and reshape the immunosuppressive tumor microenvironment ( Figure 7 b). Similarly, from the multicolor tissue immunofluorescence staining images, the number of infiltrating CD4+T and CD8+T cells in the MP@AL+aPD-L1 group was the largest, while the proportion of Foxp3+Tregs T cells was the lowest, and the level of Ki67-positive tumor cells was most significantly downregulated. This result further indicates that MP@AL NPs combined with aPD-L1 antibody treatment not only has an effective local immune activation effect and reverses the immunosuppressive tumor microenvironment, but also effectively inhibits the proliferation of tumor cells ( Figure 7 c). Subsequently, we performed ELISA to measure the levels of anticancer factors interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) in the systemic serum of mice. As a result, MP@AL+aPD-L1 triggered systemic immunity, thereby increasing the levels of cytokines in peripheral blood ( Figure 7df). In summary, based on these results, the engineered biomimetic nanosystem (MP@AL NPs) exhibited potent antitumor efficacy in vivo, especially when combined with aPD-L1 antibody therapy.

[0051] Example 5: Verification experiment of the long-term immune memory effect induced by the engineered bionic nanosystem

[0052] Long-term tumor immune memory is important for preventing tumor recurrence or metastasis. First, a subcutaneous tumor transplantation model was established in mice. After 7 days, the mice were randomly divided into 6 groups, namely the control group, MP, MP@A, MP@L, MP@AL and MP@AL+aPD-L1 group (equivalent concentrations of 5.0 mg / kg L-Arg, 1.5 mg / kg Lox and 5.0 μg / g aPD-L1). After days 0, 3, 6 and 9, the mice were given tail vein injections of 200 μL each time. After 12 days of treatment, the residual tumor was surgically removed. After 40 days, tumor cells were inoculated into the lumbar vertebrae of mice to simulate HCC-SM, and the tumors were observed for 20 days ( Figure 8 a). The MP@AL+aPD-L1 group had the longest delay in tumor recurrence compared with other groups, indicating that MP@ALNPs combined with immunotherapy can effectively prolong tumor recurrence ( Figure 8 c). In addition, at day 60, distant tumor growth was reduced in the MP@AL+aPD-L1 group, indicating inhibition of tumor recurrence and proliferation ( Figure 8 b). To evaluate the infiltration of CD4+ and CD8+ T cells in tumor samples, we also performed tissue immunofluorescence assays. The results showed that the infiltration levels of CD4+ and CD8+ T cells in the MP@AL+aPD-L1 group were significantly increased ( Figure 8 df). Memory T cells can prevent tumor recurrence. To quantify the ability of MP@AL NPs to inhibit tumor recurrence and induce long-term immune memory effects, flow cytometry was performed to examine the spleen effector memory T cells (T EM , CD44CD62L+–) ratio. The results showed that CD8+T EM and CD4+T EM The proportion of cells was the largest in the MP@AL+aPD-L1 group ( Figure 8 These findings suggest that the engineered biomimetic nanosystem (MP@AL NPs) can induce long-term immune memory effects, especially when combined with aPD-L1 antibody treatment.

[0053] This specific implementation is only an explanation of the present invention, not a limitation of the present invention. Any changes made by those skilled in the art after reading the specification of the present invention will be protected by the patent law as long as they are within the scope of the claims of the present invention.

Claims

1. An engineering bionic nanosystem, characterized in that: The nanoparticles are constructed of the fusion membrane of tumor cell membrane and pH-responsive liposome loaded with L-Arg and Lox.

2. The engineering bionic nanosystem according to claim 1, characterized in that: The preparation method of the engineering bionic nanosystem is as follows: S1. Synthesis of pH-responsive liposome-loaded L-Arg and Lox nanoparticles: Soybean lecithin, cholesterol and DSPE-Hyd-PEG-COOH were dissolved in chloroform and rotary evaporated to obtain a phospholipid membrane; PBS, Lox and L-Arg were added dropwise to the phospholipid membrane, and the membrane was ultrasonically dissolved and then extruded from the porous membrane to obtain P@AL NPs; S2. Tumor cell membrane is coated on the surface of P@AL NPs to form an engineered bionic nanosystem: The cancer cell line was disrupted using a homogenizer, the sucrose solution was mixed with the cell homogenate, and the mixture was centrifuged to obtain the tumor cell membrane; the tumor cell membrane was extruded through a porous membrane, and then P@AL NPs were added, and then co-extruded using a porous membrane. After extrusion, the excess tumor cell membrane was removed by centrifugation to obtain MP@AL NPs.

3. The engineering bionic nanosystem according to claim 1, characterized in that: In step S1, the rotary evaporation is carried out at 45-55° C. for 20-40 minutes.

4. The engineering bionic nanosystem according to claim 1, characterized in that: In step S1, when the porous membrane is extruded, a 200 nm porous membrane is first used for extrusion, and then a 100 nm porous membrane is used for extrusion.

5. The engineering bionic nanosystem according to claim 1, characterized in that: In step S2, the mass ratio of the extruded tumor cell membrane to P@AL NPs was 1:(2.5-3.5).

6. The engineering bionic nanosystem according to claim 1, characterized in that: In step S2, the centrifugation of the mixture includes two steps of centrifugation, firstly centrifugation at 2000g for 8-15 minutes, and then centrifugation of the obtained supernatant at 3000g for 25-35 minutes, and the precipitate is the tumor cell membrane.

7. The engineering bionic nanosystem according to claim 1, characterized in that: In step S2, the tumor cell membrane was extruded using a 200 nm porous membrane, and then P@AL NPs were added and co-extruded using a 100 nm porous membrane.

8. Use of the engineered bionic nanosystem according to any one of claims 1 to 7 in the preparation of anti-tumor drugs.

9. The use according to claim 8, characterized in that: The tumors include advanced liver cancer spinal metastases.

10. The application according to claim 8, characterized in that: The engineered biomimetic nanosystem is used in combination with PD-L1 antibodies.